0001121702-22-000008 | 10-K | XBRL Viewer

Print Document View Excel Document

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Current Assets:
Cash and cash equivalents	$ 5,329	$ 3,423
Short-term investments	10,661	6,279
Accounts receivable	164	86
Unbilled receivables	34	27
Prepaid expenses and other current assets	436	527
Total current assets	16,624	10,342
Restricted cash	264	264
Property and equipment, net	890	921
Right-of-use assets	2,354	2,712
Other assets	283	283
Total assets	20,415	14,522
Current Liabilities:
Accounts payable	83	60
Accrued expenses	1,136	1,297
Lease liabilities	514	457
Total current liabilities	1,733	1,814
Lease liabilities, net of current portion	2,649	3,163
Other liabilities	7	13
Total liabilities	4,389	4,990
Commitments and contingencies (Note 7)
Stockholders' Equity:
Preferred stock ($0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock ($0.01 par value per share); 60,000,000 shares authorized at December 31, 2021 and 2020, and 4,881,851 and 3,334,048 shares issued and outstanding at December 31, 2021 and 2020, respectively	49	33
Additional paid-in capital	402,283	384,758
Accumulated other comprehensive loss	(175)	(159)
Accumulated deficit	(386,131)	(375,100)
Total stockholders' equity	16,026	9,532
Total liabilities and stockholders' equity	$ 20,415	$ 14,522

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2021	Dec. 31, 2020
Preferred stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value per share (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	60,000,000	60,000,000
Common stock, shares issued	4,881,851	3,334,048
Common stock, shares outstanding	4,881,851	3,334,048

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Total revenue	$ 614	$ 799
Expenses:
Research and development	6,201	5,361
General and administrative	6,105	5,047
Total expenses	12,306	10,408
Loss from operations	(11,692)	(9,609)
Other income (expense):
Gain on investment in related party	700	0
Change in fair value of warrants	0	(957)
Loan forgiveness income	0	333
Other income (expense), net	(3)	83
Total other income (expense)	697	(541)
Loss from operations before income taxes	(10,995)	(10,150)
Income tax provision	(36)	(56)
Net loss	$ (11,031)	$ (10,206)
Basic net loss per share (in dollars per share)	$ (2.33)	$ (4.30)
Diluted net loss per share (in dollars per share)	$ (2.33)	$ (4.30)
Number of shares used in per share calculations:
Basic (in shares)	4,731,833	2,373,265
Diluted (in shares)	4,731,833	2,373,265
Grant revenue
Revenue:
Total revenue	$ 614	$ 799

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statement of Comprehensive Income [Abstract]
Net loss	$ (11,031)	$ (10,206)
Other comprehensive loss:
Change in unrealized loss on investments, net of income tax	(8)	0
Change in foreign currency translation adjustment, net of income tax	(8)	(33)
Total other comprehensive loss	(16)	(33)
Comprehensive loss	$ (11,047)	$ (10,239)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

+ Details

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (11,031)	$ (10,206)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	220	182
Change in fair value of warrants	0	957
Loan forgiveness income	0	(333)
Loss on disposal of fixed assets	0	206
Expense for 401(k) company common stock match	112	109
Stock-based compensation	1,675	739
Noncash lease expense	358	429
Deferred tax asset	35	56
Changes in operating assets and liabilities:
Accounts receivable	(78)	(14)
Unbilled receivables	(7)	(7)
Prepaid expenses and other assets	63	(69)
Accounts payable	23	(219)
Accrued expenses	(160)	99
Other liabilities	(6)	13
Lease liabilities	(457)	(601)
Net cash used in operating activities	(9,253)	(8,659)
Cash flows from investing activities
Purchase of property and equipment	(189)	(76)
Proceeds from sale of property and equipment	0	10
Purchase of investments	(10,639)	(9,279)
Proceeds from sale and maturity of short-term investments	6,250	8,700
Net cash used in investing activities	(4,578)	(645)
Cash flows from financing activities
Proceeds from warrants exercised	3,856	1,658
Proceeds from PPP loan	0	333
Proceeds from securities offerings, net of issuance costs	11,993	5,305
Taxes paid on employees' behalf related to vesting of stock awards	(103)	(17)
Net cash provided in financing activities	15,746	7,279
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(9)	(37)
Net increase (decrease) in cash, cash equivalents and restricted cash	1,906	(2,062)
Cash, cash equivalents and restricted cash at beginning of year	3,687	5,749
Cash, cash equivalents and restricted cash at end of year	5,593	3,687
Supplemental Cash Flow Disclosure:
Interest paid	$ 9	$ 8

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Series A Convertible Preferred Stock	Series A Convertible Preferred Stock Preferred Stock	Series A Convertible Preferred Stock Common Stock	Series A Convertible Preferred Stock Additional Paid-In Capital	Series B Convertible Preferred Stock	Series B Convertible Preferred Stock Common Stock	Series B Convertible Preferred Stock Additional Paid-In Capital
Balance at Dec. 31, 2019	$ (4,085)	$ 9	$ 360,926	$ (126)	$ (364,894)		$ 0
Balance (in shares) at Dec. 31, 2019		933,423					796
Increase (decrease) in stockholders' equity
Stock-based compensation expense	864		864
Issuance of common stock for 401(k) match	$ 112		112
Issuance of common stock for 401k match (in shares)	20,788	20,788
Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes	$ 0		0
Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes (in shares)		6,006
Taxes paid on employees' behalf related to vesting of stock awards	(17)		(17)
Issuance of common stock for warrant exercises	1,658	$ 2	1,656
Issuance of common stock for warrant exercises (in shares)		207,296
Issuance of stock	5,305	$ 13	5,292			$ 0		$ 2	$ (2)	$ 0	$ 7	$ (7)
Issuance of stock (in shares)		1,348,285					(796)	99,500			718,750
Reclassification of warrant liability to equity	15,934		15,934
Effect of foreign currency translation	(33)			(33)
Net loss	(10,206)				(10,206)
Balance at Dec. 31, 2020	9,532	$ 33	384,758	(159)	(375,100)		$ 0
Balance (in shares) at Dec. 31, 2020		3,334,048					0
Series B Convertible Preferred Stock, balance at Dec. 31, 2019	$ 0
Series B Convertible Preferred Stock, balance (in shares) at Dec. 31, 2019	5,750
Increase (Decrease) in Temporary Equity
Issuance of common stock upon conversion of Series B Convertible Preferred Stock (in shares)	(5,750)
Issuance of preferred stock in connection with private offering (in shares)	0
Series B Convertible Preferred Stock, balance at Dec. 31, 2020	$ 0
Series B Convertible Preferred Stock, balance (in shares) at Dec. 31, 2020	0
Increase (decrease) in stockholders' equity
Stock-based compensation expense	$ 1,685		1,685
Issuance of common stock for 401(k) match	$ 109		109
Issuance of common stock for 401k match (in shares)	13,611	13,611
Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes	$ 0		0
Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes (in shares)		12,219
Taxes paid on employees' behalf related to vesting of stock awards	(102)		(102)
Issuance of common stock for warrant exercises	3,856	$ 5	3,851
Issuance of common stock for warrant exercises (in shares)		481,973
Issuance of stock	11,993	$ 11	11,982
Issuance of stock (in shares)		1,040,000
Effect of foreign currency translation	(16)			(16)
Net loss	(11,031)				(11,031)
Balance at Dec. 31, 2021	16,026	$ 49	$ 402,283	$ (175)	$ (386,131)		$ 0
Balance (in shares) at Dec. 31, 2021		4,881,851					0
Series B Convertible Preferred Stock, balance at Dec. 31, 2021	$ 0
Series B Convertible Preferred Stock, balance (in shares) at Dec. 31, 2021	0

CONSOLIDATED STATEMENTS OF SERIES B CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) (Parenthetical) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statement of Stockholders' Equity [Abstract]
Offering costs	$ 747	$ 425

Nature of Business and Basis of Presentation	12 Months Ended
Nature of Business and Basis of Presentation	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Basis of Presentation	Nature of Business and Basis of Presentation Yield10 Bioscience, Inc. ("Yield10" or the "Company") is an agricultural bioscience company that is developing the oilseed Camelina sativa ("Camelina") as a platform crop for large scale production of low carbon sustainable seed products to address 1) petroleum replacement markets: Camelina oil for use as a biofuel feedstock and PHA Bioplastics produced in Camelina seed for use as a biodegradable bioplastic; and 2) food and nutrition markets: omega-3 (DHA+EPA) oils produced in Camelina seed for aquaculture and nutraceuticals; and protein meal for animal feed markets. The commercial plan is based on developing and releasing a series of proprietary elite Camelina seed varieties incorporating genetic traits from the Company's development pipeline which offer improved on-farm performance that will lead to increased acreage and seed product revenue. Yield10 also plans to create additional value for its shareholders by licensing yield and seed oil traits from the Company's pipeline to large seed companies for commercialization in major food crops, including corn, soybean and canola. Yield10 is headquartered in Woburn, Massachusetts and has an Oilseed Center of Excellence in Saskatoon, Saskatchewan, Canada. The accompanying consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business. With the exception of a single year, the Company has recorded losses since its initial founding, including its fiscal year ending December 31, 2021. During the year ended December 31, 2021, the Company was successful in raising capital to fund its operations, ending the year with unrestricted cash, cash equivalents and short-term investments of $15,990. The Company follows the guidance of Accounting Standards Codification ("ASC") Topic 205-40, Presentation of Financial Statements-Going Concern, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its consolidated financial statements are issued. The Company's ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing through, among other sources, public or private equity financing, secured or unsecured debt financing, equity or debt bridge financing, warrant holders' ability and willingness to exercise the Company's outstanding warrants, additional research grants or collaborative arrangements with third parties, as to which no assurance can be given. Management does not know whether additional financing will be available on terms favorable or acceptable to the Company when needed, if at all. If adequate additional funds are not available when required, management will be forced to curtail the Company's research efforts, explore strategic alternatives and/or wind down the Company's operations and pursue options for liquidating its remaining assets, including intellectual property and equipment. Based on its current cash forecast, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from when these consolidated financial statements are available to be issued, which raises substantial doubt as to the Company's ability to continue as a going concern. This forecast of cash resource is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors. If the Company issues equity or debt securities to raise additional funds, (i) the Company may incur fees associated with such issuance, (ii) its existing stockholders may experience dilution from the issuance of new equity securities, (iii) the Company may incur ongoing interest expense and be required to grant a security interest in Company assets in connection with any debt issuance, and (iv) the new equity or debt securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. In addition, utilization of the Company’s net operating loss and research and development credit carryforwards may be subject to significant annual limitations under Section 382 of the Internal Revenue Code of 1986, as amended, (the "Internal Revenue Code") due to ownership changes resulting from equity financing transactions. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies or grant licenses on terms that are not favorable to the Company. On January 30, 2020, the World Health Organization ("WHO") announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China ("COVID-19") and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 pandemic continues to evolve as of the date of this report. As such, the full magnitude that the pandemic will have on the Company's financial condition, liquidity and future results of operations is uncertain. While management currently expects the impact of COVID-19 to be temporary, there is uncertainty around the duration and its broader impact on the economy and therefore the effects it will have on Yield10's financial condition, liquidity, operations, suppliers, industry, and workforce in future periods.

Summary of Significant Accounting Policies

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

Basis of Presentation

The accompanying consolidated financial statements are presented in U.S. dollars and are prepared in accordance with accounting standards set by the Financial Accounting Standards Board ("FASB"). The FASB sets generally accepted accounting principles ("GAAP") that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported. References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification ("ASC").

Principles of Consolidation

The Company's consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America. The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany transactions were eliminated, including transactions with its subsidiaries, Metabolix Oilseeds, Inc. ("MOI") and Yield10 Bioscience Securities Corp.

Reverse Stock Split

On January 15, 2020, the Company effected a 1-for-40 reverse stock split of its common stock. Unless otherwise indicated, all share amounts, per share data, share prices, and conversion rates set forth in these notes and the accompanying consolidated financial statements have, where applicable, been adjusted retroactively to reflect this reverse stock split.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's consolidated balance sheets included herein:


	December 31, 2021		December 31, 2020
Cash and cash equivalents	$	5,329	$	3,423
Restricted cash	264		264
Total cash, cash equivalents and restricted cash	$	5,593	$	3,687

Amounts included in restricted cash represent those required to be set aside by contractual agreement. Restricted cash of $264 at December 31, 2021 and December 31, 2020, primarily consists of funds held in connection with the Company's lease agreement for its Woburn, Massachusetts facility.

Investments

Investments represent holdings of available-for-sale marketable debt securities acquired in accordance with the Company's investment policy. The Company considers all investments purchased with an original maturity date of ninety days or more at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments. All other investments are classified as long-term. The Company held no long-term investments at December 31, 2021 and December 31, 2020.

Investments in marketable debt securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders' equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred. Other-than-temporary impairments of equity investments are recognized in the Company's statements of operations if the Company has experienced a credit loss and has the intent to sell the investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis. Realized gains and losses, dividends, interest income and declines in value judged to be other-than-temporary credit losses are included in other income (expense). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion together with interest on securities are included in interest income on the Company's consolidated statements of operations. The cost of marketable securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of other income (expense).

Foreign Currency Translation

Foreign denominated assets and liabilities of the Company's wholly-owned foreign subsidiary are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date. Revenues and expenses are translated at average exchange rates prevailing during the period. Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the consolidated balance sheet. When the Company dissolves, sells or substantially sells all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its consolidated statement of operations during the fiscal period when the dissolution or sale occurs.

Comprehensive Loss

Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net loss. The Company includes unrealized gains and losses on debt securities and foreign currency translation adjustments in other comprehensive loss.

Concentration of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents, restricted cash, short-term investments and accounts receivable. The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes. Investments are acquired in accordance with the Company's investment policy which establishes a concentration limit per issuer.

At December 31, 2021, all of the Company's accounts and unbilled receivables of $198 were due from Michigan State University ("MSU") for support to a Department of Energy funded grant under which the Company serves as a subcontractor. The Company believes these receivables have a low risk of default. At December 31, 2020, $86 of the Company's total billed and unbilled receivables of $113 were due from a Canadian research grant awarded to MOI through the Industrial Research Assistance Program. The remaining balance of $27 was due from the MSU subcontract. The MSU sub-award represented 94% of government grant revenue earned during the year ended December 31, 2021.

Fair Value Measurements

The carrying amounts of the Company's financial instruments as of December 31, 2021 and December 31, 2020, which include cash equivalents, restricted cash, accounts receivable, unbilled receivables, accounts payable, and accrued expenses, approximate their fair values due to the short-term nature of these instruments. See Note 4 for further discussion on fair value measurements.

Segment Information

The accounting guidance for segment reporting establishes standards for reporting information on operating segments in annual financial statements. The Company is an agricultural bioscience company operating in one segment, which is the development of new technologies to enable step-change increases in crop yield to enhance global food security and production of specialty oils and niche crops. The Company's chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company's consolidated operating results.

Property and Equipment

Property and equipment are stated at cost less accumulated depreciation and amortization. Repairs and maintenance are charged to operating expense as incurred. Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:


Asset Description						Estimated Useful Life (years)
Equipment						3
Furniture and fixtures						5
Software						3
Leasehold improvements						Shorter of useful life or term of lease

Lease Accounting

As a lessee, the Company follows the lease accounting guidance codified in ASC 842. A lease is classified as a finance lease if any of five criteria described in the guidance apply to the lease and any lease not classified as a finance lease is classified as an operating lease with expense recognition occurring on a straight-line basis over the term of the lease. Under ASC 842, the Company records a lease liability on the commencement date of a lease calculated as the present value of the lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the Company's incremental borrowing rate. A right-of-use asset equal to the lease liability is also recorded with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs and lessor lease incentives that may be present within the terms of the lease. The Company adopted the short-term lease exception that permits lessees to omit leases with terms of twelve months or less from the accounting requirements of ASC 842.

Impairment of Long-Lived Assets

Long-lived assets, such as property and equipment and right-of-use assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Accounting guidance further requires that companies recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and measure an impairment loss as the difference between the carrying amount and fair value of the asset.

Grant Revenue

The Company's source of continuing revenue is from its government research grants in which it serves as either the primary contractor or as a subcontractor. These grants are considered an ongoing major and central operation of the Company's business. Revenue is earned as research expenses related to the grants are incurred. Revenue earned on government grants, but not yet invoiced as of the balance sheet date, are recorded as unbilled receivables in the accompanying consolidated balance sheets for the years ended December 31, 2021 and December 31, 2020. Funds received from government grants in advance of work being performed, if any, are recorded as deferred revenue until earned.

Research and Development

All costs associated with internal research and development are expensed as incurred. Research and development expenses include, among others, direct costs for salaries, employee benefits, subcontractors, crop trials, regulatory activities, facility related expenses, depreciation and amortization, and stock-based compensation. Costs incurred in connection with government research grants are recorded as research and development expenses.

General and Administrative Expenses

The Company's general and administrative expense includes costs for salaries, employee benefits, facilities expenses, consulting and professional service fees, travel expenses, depreciation and amortization expenses and office related expenses incurred to support the administrative operations of the Company.

Intellectual Property Costs

The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the consolidated statement of operations.

Stock-Based Compensation

All stock-based payments to employees, members of the Board of Directors and non-employees are recognized within operating expense based on the straight-line recognition of their grant date fair value over the period during which the recipient is required to provide service in exchange for the award. See Note 10 for a description of the types of stock-based awards granted, the compensation expense related to such awards and detail of equity-based awards outstanding.

Basic and Diluted Net Loss per Share

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding. Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of dilutive common shares outstanding during the period. Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method, as well as weighted shares outstanding of any potential (unissued) shares of common stock from restricted stock units and the conversion of preferred stock. In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced. Therefore, in periods when a loss is reported, basic and dilutive loss per share are the same. Common stock equivalents include stock options, restricted stock awards, convertible preferred stock and warrants.

The Company follows the two-class method when computing net loss per share, when it has issued shares that meet the definition of participating securities. The two-class method determines net income per share for each class of common and participating securities according to dividends declared or accumulated and participating rights in undistributed earnings. The two-class method requires income available to common stockholders to be allocated between common and participating securities based on their respective rights to receive dividends. In periods of net loss, a participating security that does not have a contractual obligation to share in the loss is not allocated a portion of the net loss when determining loss per share under the two-class method.

The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their antidilutive effect:


	Year Ended December 31,
	2021	2020
Options	722,765	339,108
Restricted stock awards	9,430	8,500


Warrants	2,361,726	2,843,699
Total	3,093,921	3,191,307

Income Taxes

The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company's tax returns. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. A valuation allowance is provided to reduce deferred tax assets to a level which, more likely than not, will be realized.

The Company accounts for uncertain tax positions using a "more-likely-than-not" threshold for recognizing and resolving uncertain tax positions. The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position. The provision for income taxes includes the effects of any resulting tax reserves or unrecognized tax benefits that are considered appropriate as well as the related net interest and penalties, if any. The Company evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions.

See Note 13 for further discussion of income taxes. The Company had no amounts recorded for unrecognized tax benefits as of December 31, 2021 and 2020.

Recent Accounting Standards Changes

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date.

In December 2019, the FASB issued Accounting Standards Update No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. This standard removes certain exceptions to the general principles in Topic 740 and simplifies certain other aspects of the accounting for income taxes. This standard became effective for the Company on January 1, 2021, and did not have a material impact on the Company's consolidated financial statements and related disclosures.

The following new pronouncement is not yet effective but may impact the Company's consolidated financial statements in the future.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date as the initial pronouncement. This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment. This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The guidance is effective for

fiscal years beginning after December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition, and interim periods within those fiscal years. The Company is currently evaluating the impact this guidance will have on its consolidated financial statements.

Investments

12 Months Ended

Dec. 31, 2021

Investments, Debt and Equity Securities [Abstract]

Investments

INVESTMENTS

The Company's investments consist of the following:


	Accumulated Cost at December 31, 2021		Unrealized				Market Value at December 31, 2021
			Gain		(Loss)
Short-term investments
U.S. government and agency securities	$	10,669	$	—	$	(8)	$	10,661
Total	$	10,669	$	—	$	(8)	$	10,661


	Accumulated Cost at December 31, 2020		Unrealized				Market Value at December 31, 2020
			Gain		(Loss)
Short-term investments
U.S. government and agency securities	$	6,279	$	—	$	—	$	6,279
Total	$	6,279	$	—	$	—	$	6,279

Fair Value Measurements

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Fair Value Measurements

The Company has certain financial assets recorded at fair value which have been classified as Level 1 and Level 2 within the fair value hierarchy as described in the accounting standards for fair value measurements. Fair value is the price that would be received from the sale of an asset or the price paid to transfer a liability in an orderly transaction between independent market participants at the measurement date. Fair values determined by Level 1 inputs utilize observable data such as quoted prices in active markets for identical instruments. Fair values determined by Level 2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly. Fair values determined by Level 3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions. The fair value hierarchy level is determined by the lowest level of significant input.

The Company’s financial assets classified as Level 2 at December 31, 2021 and December 31, 2020 were initially valued at the transaction price and subsequently valued utilizing third-party pricing services. Because the Company’s investment portfolio may include securities that do not always trade on a daily basis, the pricing services use many observable market inputs to determine value including reportable trades, benchmark yields and benchmarking of like securities. The Company validates the prices provided by the third-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources. After completing the validation procedures, the Company did not adjust or override any fair value measurements provided by these pricing services as of December 31, 2021 and December 31, 2020.

The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2021 and December 31, 2020 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value.


	Fair value measurements at December 31, 2021
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		December 31, 2021
Assets
Cash equivalents:
Money market funds	$	4,878	$	—	$	—	$	4,878

Short-term investments:
U.S. government and agency securities	—		10,661		—		10,661
Total assets	$	4,878	$	10,661	$	—	$	15,539


	Fair value measurements at December 31, 2020
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		December 31, 2020
Assets
Cash equivalents:
Money market funds	$	2,873	$	—	$	—	$	2,873
Short-term investments:
U.S. government and agency securities	—		6,279		—		6,279
Total assets	$	2,873	$	6,279	$	—	$	9,152

There were no transfers of financial assets or liabilities between category levels for the years ended December 31, 2021 and December 31, 2020.

During November 2019, the Company issued Series A Warrants and Series B Warrants in two concurrent securities offerings that were considered free standing financial instruments, were legally detachable and separately exercisable from the common and preferred stock issued in the two offerings. The Company initially determined that all of the Series A Warrants and Series B Warrants should be classified as a warrant liability in accordance with ASC 480, Distinguishing Liabilities from Equity, and recognized at their inception date fair value due to the insufficiency of common shares available to permit their exercise. The warrant liability met Level 3 classification criteria for classification within the fair value hierarchy. On January 15, 2020, the Company filed an amendment to its Certificate of Incorporation with the State of Delaware to effect a 1-for-40 reverse stock split. As a result of the reverse stock split, the Company's number of authorized but unissued shares of Common Stock increased significantly and the Series A Warrants and Series B Warrants became eligible for exercise, resulting reclassification of the warrant liability to equity. Prior to reclassification as equity, on January 15, 2020, the Company adjusted the warrant liability to its then $15,934 fair value using the Black-Scholes valuation model, recording a loss on the adjustment to fair value of $957.

The following tables show a reconciliation of the beginning and ending balances for the Level 3 warrant liability for the year ending December 31, 2020.


	Year ended December 31, 2020
Warrant liability, December 31, 2019	$	14,977
Recognized loss from mark-to-market adjustment prior to reclassification of warrant liability to equity	957
Reclassification from warrant liability to equity	(15,934)
Warrant liability, December 31, 2020	$	—

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Property and Equipment, Net

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment [Abstract]

Property and Equipment, Net

Property and equipment consist of the following:


	Year ended December 31,
	2021		2020
Equipment	$	581	$	766
Furniture and fixtures	43		43
Leasehold improvements	1,420		1,414
Software	14		22
Total property and equipment, at cost	2,058		2,245
Less: accumulated depreciation and amortization	(1,168)		(1,324)
Property and equipment, net	$	890	$	921

Depreciation and amortization expense for the years ended December 31, 2021 and December 31, 2020, was $220 and $182, respectively.

Accrued Expenses

12 Months Ended

Dec. 31, 2021

Payables and Accruals [Abstract]

Accrued Expenses

Accrued expenses consist of the following:


	Year ended December 31,
	2021		2020
Employee compensation and benefits	$	452	$	620
Leased facilities	71		188
Professional services	264		235
Field trials and related expenses	97		52
Other	252		202
Total accrued expenses	$	1,136	$	1,297

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Contractual Commitments Exclusive Collaboration Agreement with Rothamsted Research ("Rothamsted") On November 12, 2020, the Company signed an exclusive collaboration agreement with UK-based Rothamsted to support Rothamsted’s program to develop omega-3 oils in Camelina sativa. Under the agreement, Yield10 is providing Rothamsted with financial support for ongoing research including further DHA+EPA trait improvement, field testing and nutritional studies. The Company will pay Rothamsted quarterly research funding and option fees of $31 for two years totaling $250, of which $125 remains outstanding as of December 31, 2021. Included within the agreement, the Company has an exclusive two-year option to sign a global, exclusive or non-exclusive license agreement to the technology. The current agreement terminates automatically on its second anniversary unless terminated earlier in accordance with the terms of the agreement. License Agreement with the University of Massachusetts ("UMASS") Pursuant to a license agreement with UMASS dated as of June 30, 2015 and subsequently amended, the Company has an exclusive, worldwide license under certain patents and patent applications, including issued patents covering the Company's yield trait gene C3003, relating to the manufacture of plants with enhanced photosynthesis. The agreement provides an exclusive, worldwide license to make, have made, use, offer for sale and import any transgenic plant seed or plant grown from transgenic plant material for sale to a farmer or grower that is derived from (in whole or in part) one or more issued or pending claims of the licensed patents or patent applications. Pursuant to the UMASS license agreement, the Company is required to use diligent efforts to develop licensed products throughout the field of use and to introduce licensed products into the commercial market. The Company's failure to achieve any milestone provided for under the agreement would give UMASS the right to terminate the agreement, following a notice period, unless the Company is able to reach agreement with UMASS as to a potential adjustment to the applicable milestone. The Company is obligated to pay UMASS milestone payments relating to regulatory filings and approvals covered by the agreement, royalties on any sales of licensed products following regulatory approval, as well as a percentage of any sublicense income, if any, related to the licensed products. The Company or UMASS may terminate the agreement in accordance with the terms of the agreement. License Agreement with the University of Missouri ("UM") Pursuant to a license agreement with UM dated as of May 17, 2018, Yield10 has an exclusive, worldwide license to two novel gene technologies to boost oil content in crops. Both technologies are based on significant new discoveries around the function and regulation of ACCase, a key rate-limiting enzyme involved in oil production. The UM license was expanded during May 2019 to include an exclusive worldwide license to a third gene in the ACCase complex, that the Company has designated C3012, that may complement the activity of C3007 to boost oil content in crops. Pursuant to the UM license agreement, the Company is required to use diligent efforts to develop licensed products throughout the licensed field and to introduce licensed products into the commercial market. The Company's failure to achieve any milestone provided for under the license agreement would give UM the right to terminate the license agreement or render it nonexclusive, unless the Company is able to reach agreement with UM as to the potential adjustment of the applicable milestone. The Company is obligated to pay UM a license execution payment, milestone payments relating to any regulatory filings and approvals covered by the license agreement, royalties on any sales of licensed products following regulatory approval, as well as a percentage of any sublicense royalties, if any, related to the licensed products. The Company or UM may terminate the license agreement in accordance with the terms of the agreement. Facility Leases The Company leases facilities under non-cancelable leases expiring at various dates through November 30, 2026. See Note 11. Litigation From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not currently aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on the business, financial condition or the results of operations. Guarantees As of December 31, 2021, and December 31, 2020, the Company did not have significant liabilities recorded for guarantees. The Company enters into indemnification provisions under various agreements with other companies in the ordinary course of business, typically with business partners, contractors, and customers. Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of its activities. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited. However, to date Yield10 Bioscience has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of these agreements is minimal. Accordingly, the Company has no liabilities recorded for these agreements as of December 31, 2021 and December 31, 2020.

License Agreements	12 Months Ended
License Agreements	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License Agreements	License Agreements In August 2020, the Company entered into a non-exclusive research agreement with GDM ("GDM"), a company specialized in plant genetics, to evaluate novel traits in soybean. Under the terms of the agreement, GDM is working with the Company's yield traits within its research and development program as a strategy to improve soybean yield performance and sustainability. The research agreement includes three novel yield traits in the first phase with the potential to expand the program to more traits in the future. In October 2019, the Company granted a non-exclusive license to J. R. Simplot ("Simplot"), to evaluate three of the Company's novel traits in potato. Under the agreement, Simplot plans to conduct research with the yield traits C3003, C3004 and C4001 within its research and development program as a strategy to improve crop performance and sustainability. In September 2018, the Company granted a three-year, non-exclusive license to Forage Genetics International, LLC ("Forage Genetics"), a subsidiary of Land O'Lakes, Inc., to evaluate five of the Company's novel traits in forage sorghum. The traits included in the research license include C3003 as well as four traits from the Company's GRAIN platform, C4001, C4002, C4003 and C4029. The key objective of the licensing agreement is to provide Forage Genetics with novel traits to test alone and/or in any combination in sorghum that may lead to the identification of new yield traits for potential future licensing from the Company for development and commercial deployment. In September 2021, the Company and Forage Genetics amended the license agreement in order to extend it for a fourth year. In September 2017, the Company granted a license to Bayer to evaluate the Company's novel C3003 and C3004 yield traits in soybean. Under this license, Bayer has the non-exclusive right to begin work with C3003 in its soybean program as a strategy to improve seed yield. Bayer may also conduct research with the Company's C3004 yield trait, a trait accessible through genome editing, in combination with C3003 to evaluate the effectiveness of the combination in improving seed yield in soybean. In August 2019, the Company expanded its 2017 non-exclusive research license with Bayer, for soybean crop research to include a new discovery related to its C3004 yield trait gene. None of these research arrangements provide significant licensing revenue to the Company while the third parties perform trait evaluations.

Capital Stock and Warrants

12 Months Ended

Dec. 31, 2021

Equity [Abstract]

Capital Stock and Warrants

Common Stock

Registered Public Offerings

On February 3, 2021, the Company completed a public offering of 1,040,000 shares of its common stock at a public offering price of $12.25 per share for total gross proceeds of $12,740 before issuance costs of $747.

On August 26, 2020, the Company completed a public offering of 951,835 shares of its common stock at a public

offering price of $4.25 for total gross proceeds of $4,045 before issuance costs of $425.

Private Placement

Concurrent with the registered public offering completed on August 26, 2020, as described above, the Company completed a separate private placement offering of 396,450 shares of its common stock to certain existing shareholders at the same $4.25 price offered to investors in the public offering. Proceeds from this private placement were $1,685.

Reverse Stock Split

On January 15, 2020, the Company completed a 1-for-40 reverse stock split ("reverse stock split") of its common stock by filing a certificate of amendment (the "Charter Amendment") with the State of Delaware to amend its certificate of incorporation. The ratio for the reverse stock split was determined by the Company's board of directors following approval by stockholders at the Company's special meeting held on January 9, 2020. The reverse stock split had the effect of increasing the Company's common shares available for issuance by reducing issued and outstanding common shares by a divisible factor of 40 while its authorized shares remained at its current 60 million shares. Proportional adjustments were made to the Company's outstanding stock options and warrants and to the number of shares issued and issuable under the Company's equity compensation plans.

November 2019 Concurrent Securities Offerings

On November 19, 2019, the Company closed on concurrent public and private securities offerings that included the following: common stock, Series A Convertible Preferred Stock, Series B Convertible Preferred Stock, Series A Warrants and Series B Warrants. Combined gross cash proceeds from the offerings totaled $11,500, before issuance costs of $1,254.

As of the November 19, 2019 closing date of the two offerings, the Company did not have sufficient authorized and available shares of common stock to permit conversion of the Series B Convertible Preferred Stock sold in the private placement or to permit the exercise of the 2,875,000 combined Series A Warrants and Series B Warrants issued under both the public and the private offerings. The Series B Convertible Preferred Shares and the warrants were not convertible or exercisable until more shares of common stock became available for issuance through the Company's filing of the Charter Amendment for the Reverse Stock Split described above. Upon the filing of the amendment on January 15, 2020, all of the Series B Convertible Preferred Stock sold in the private placement automatically converted into 718,750 shares of common stock and the Series A Warrants and Series B Warrants issued in both offerings became eligible for exercise.

At the time of their issuance, the Company determined that all of the Series A Warrants and Series B Warrants should be classified as a warrant liability and recorded at an inception date fair value of $24,518 due to the insufficiency of common shares available to permit their exercise. The Company re-measured the fair value of the warrants on December 31, 2019 and again on January 15, 2020 (the date of filing the Charter Amendment to increase available shares of common stock), resulting in, respectively, the recognition of a gain of $9,541 followed by a loss of $957, due to the change in fair value at each valuation date. By filing the Charter Amendment and effecting the 1-for-40 Reverse Stock Split, the Company's outstanding common shares were reduced by a divisible factor of 40 while authorized common shares remained at the current 60 million shares. As a result of this corporate action, sufficient shares of authorized, but unissued shares of common stock became available for Series A and Series B warrant holders to exercise their warrants resulting in their reclassification from warrant liability to equity on the date of filing the Charter Amendment.

Preferred Stock

The Company's certificate of incorporation, as amended and restated, authorizes it to issue up to 5,000,000 shares of $0.01 par value preferred stock.

Description of Series A Convertible Preferred Stock

The November 2019 public offering of the Company's securities included the issuance of 2,504 shares of Series A Convertible Preferred Stock. Each Series A Convertible Preferred Share was convertible into 125 shares of common stock at a conversion price of $8.00 per share. All of the 2,504 shares of the Series A Convertible Preferred Stock converted to 313,000 shares of common stock by April 30, 2020.

Description of Series B Convertible Preferred Stock

The November 2019 private offering of the Company's securities included the issuance of 5,750 shares of Series B Convertible Preferred Stock. Each share of Series B Convertible Preferred Stock was convertible into 125 shares of common stock at a conversion price of $8.00 per share. All of the Series B Convertible Preferred Stock converted automatically to 718,750 shares of common stock on January 15, 2020, upon the Company's filing of a Charter Amendment for the reverse stock split described above.

When converted, the shares of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock were restored to the status of authorized but unissued shares of preferred stock, subject to reissuance by the board of directors.

Warrants

The following table summarizes information with regard to outstanding warrants to purchase common stock as of December 31, 2021:


Issuance	Number of Common Shares Issuable Upon Exercise of Outstanding Warrants	Exercise Price		Expiration Date
November 2019 Public Offering - Series A	352,703	$	8.00	May 19, 2022
November 2019 Public Offering - Series B	395,528	$	8.00	May 19, 2027
November 2019 Private Placement - Series A	718,750	$	8.00	May 19, 2022
November 2019 Private Placement - Series B	718,750	$	8.00	May 19, 2027
December 2017 Public Offering - Series A	160,975	$	90.00	December 21, 2022
July 2017 Registered Direct Offering	14,270	$	201.60	January 7, 2024
Consultant	750	$	116.00	September 11, 2024
Total	2,361,726

During the year ended December 31, 2021, a combined total of 481,973 Series A and Series B warrants issued in the Company's November 2019 securities offering were exercised by warrant holders, providing the Company with $3,856 in cash proceeds.

Reserved Shares

The following shares of common stock were reserved for future issuance upon exercise of stock options, vesting of Restricted Stock Units ("RSUs") and conversion of outstanding warrants:


	December 31, 2021	December 31, 2020
Stock Options	722,765	339,108
RSUs	9,430	8,500
Warrants	2,361,726	2,843,699
Total number of common shares reserved for future issuance	3,093,921	3,191,307

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Stock-Based Compensation

12 Months Ended

Dec. 31, 2021

Share-based Payment Arrangement [Abstract]

Stock-Based Compensation

Stock Option Plans

The Company adopted a stock plan in 2006 (the "2006 Plan"), which provided for the granting of incentive stock options, non-qualified stock options, stock appreciation rights, deferred stock awards, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights. In October 2014, the 2006 Plan was terminated, and the Company adopted a new plan (the "2014 Plan"). No further grants or awards were subsequently made under the 2006 Plan. A total of 3,662 options were awarded from the 2006 Plan and as of December 31, 2021, 364 of these options remain outstanding and eligible for future exercise.

The 2014 Plan provides for the granting of incentive stock options, non-qualified stock options, stock appreciation rights, deferred stock awards, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights. In May 2018, the 2014 Plan was terminated, and the Company adopted a new 2018 Stock Option and Incentive Plan, which was amended in May 2020 (the "2018 Stock Plan"). A total of 16,896 options were awarded from the 2014 Plan and as of December 31, 2021, 16,108 of these options remain outstanding and eligible for future exercise. A total of 3,619 restricted stock awards were awarded from the 2014 Plan and as of December 31, 2021, all of these restricted stock awards have vested. No further stock awards may be issued from the 2014 Plan.

The 2018 Stock Plan initially reserved for issuance 32,500 shares of the Company's common stock for grants of incentive stock options, non-qualified stock options, stock grants and other stock-based awards. In accordance with the terms of the 2018 Stock Plan, beginning on the first day in January 2019, the Company's Board of Directors has annually approved the addition of shares to the 2018 Stock Plan in amounts equal to 5% of the outstanding shares of the Company's common stock on the day prior to the increase. Total shares added to the 2018 Plan from these annual additions through January 2022 have amounted to 469,998. At its annual meetings of stockholders held on May 19, 2020 and May 24, 2021, stockholders approved amendments to add 250,000 and 300,000 more shares, respectively, to the 2018 Plan. As of December 31, 2021, a total of 745,184 options and restricted stock awards have been issued from the 2018 Stock Plan, and as of that date, 715,244 options and restricted stock awards remain outstanding.

Expense Information for Stock Awards

The Company recognized stock-based compensation expense, related to employee stock awards, including awards to non-employees and members of the Board of Directors, of $1,675 and $739 for the years ended December 31, 2021 and 2020, respectively. At December 31, 2021, there was approximately $4,036 of stock-based compensation expense related to unvested awards not yet recognized which is expected to be recognized over a weighted average period of 2.96 years.

Stock Options

Options granted under the 2006 Plan, 2014 Plan and 2018 Stock Plan generally vest ratably over periods of one to four years from the date of hire for new employees, the date of award for existing employees, or date of commencement of services with the Company for non-employees, and generally expire ten years from the date of issuance. The Company's policy is to issue new shares upon the exercise of stock options.

A summary of the activity related to the shares of common stock covered by outstanding options is as follows:


	Number of Shares	Weighted Average Exercise Price		Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Balance at December 31, 2020	339,108	$	32.39
Granted	386,017	10.08
Exercised	—	—
Forfeited	(1,509)	12.92
Expired	(851)	1,131.62
Balance at December 31, 2021	722,765	19.22		8.79	$	—
Vested and expected to vest at December 31, 2021	722,765	19.22		8.79	$	—
Exercisable at December 31, 2021	213,156	43.15		8.07	$	—

The weighted average grant date fair value per share of options granted during fiscal years 2021 and 2020, was $8.99 and $5.31, respectively. No options were exercised during 2021 and 2020, and therefore the intrinsic value for exercised options during the two years was not applicable. The weighted average remaining contractual term for options outstanding as of December 31, 2021 was 8.79 years.

For the years ended December 31, 2021, and 2020, the Company determined the fair value of stock options using the Black-Scholes option pricing model with the following assumptions for option grants, respectively:


	Year Ended December 31,
	2021	2020
Expected dividend yield	—	—
Risk-free rate	0.7% - 1.7%	0.5% - 1.9%
Expected option term (in years)	6.1 - 10.0	6.1 - 10.0
Volatility	118% - 128%	111% - 129%

The Company determined its volatility assumption based on actual market price fluctuations experienced during its trading history. The risk-free interest rate used for each grant is equal to the U.S. Treasury yield curve in effect at the time of grant for instruments with a term similar to the expected life of the related option. The expected term of the options is based upon evaluation of historical and expected future exercise behavior.

The stock price volatility and expected terms utilized in the calculation involve management's best estimates at that time, both of which impact the fair value of the option calculated under the Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option. The accounting standard for stock-based compensation requires that the Company recognize compensation expense for only the portion of options that vest. The Company recognizes stock option forfeitures resulting from award terminations in the period in which the forfeiture occurs.

Restricted Stock Units ("RSUs")

The Company records stock compensation expense for RSUs on a straight-line basis over their requisite service period, which approximates the vesting period, based on each RSU's award date market value. As RSUs vests, the Company withholds a number of shares from its employees with an aggregate fair market value equal to the minimum tax withholding amount (unless the employee makes other arrangements for payment of the tax withholding) from the common stock issuable at the vest date. The Company then pays the minimum required income tax for the employees. During the years ended December 31, 2021 and December 31, 2020, the Company withheld vested shares with a fair value of $102 and $17, respectively, to pay for minimum tax withholding associated with RSU vesting.

A summary of RSU activity for the year ended December 31, 2021 is as follows:


	Number of RSUs	Weighted Average Remaining Contractual Life (years)
Outstanding at December 31, 2020	8,500
Awarded	18,862
Released	(17,932)
Forfeited	—
Outstanding at December 31, 2021	9,430	0.16

Weighted average remaining recognition period (years)	0.16

Leases

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

LEASES

Lease Accounting

As a lessee, the Company follows the lease accounting guidance codified in ASC 842. Under ASC 842, a lease is classified as a finance lease if any of five criteria described in the guidance apply to the lease. Any lease not classified as a finance lease is classified as an operating lease with expense recognition occurring on a straight-line basis over the term of the lease. The Company's existing lease subject to ASC 842 meets the standards for operating lease classification.

Under ASC 842, a lease liability is recorded on the commencement date of a lease and is calculated as the present value of the remaining lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the lessee's incremental borrowing rate. A right-of-use asset equal to the lease liability is also recorded with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs and lessor lease incentives that may be present within the terms of the lease. The Company adopted the short-term lease exception that permits lessees to omit leases with terms of twelve months or less from the accounting requirements of ASC 842.

Maturity Analysis of Lease Liabilities

The Company's Woburn, Massachusetts facility is the only lease included in the Company's right-of-use assets and corresponding lease liabilities. No other active real estate or equipment leases fall within the scope of ASC 842. At December 31, 2021, the Company's lease liability related to its Woburn facility will mature as follows:


Year ended December 31,	Undiscounted Cash Flows
2022	$	726
2023	749
2024	771
2025	793
2026	747
Total undiscounted future lease payments	3,786
Amount of lease payments representing interest	(623)
Total lease liabilities	$	3,163
Short-term lease liabilities	$	514
Long-term lease liabilities	$	2,649

Quantitative Disclosure of Lease Costs


	Year Ended December 31,
	2021		2020
Lease cost:
Operating lease cost	$	605	$	688
Short-term lease cost	655		676
Sublease income	(616)		(560)
Total lease cost, net	$	644	$	804


Other information as of:	December 31, 2021	December 31, 2020
Weighted-average remaining lease term (years)	4.9	5.9
Weighted-average discount rate	7.25%	7.25%

Real Estate Leases

During 2016, the Company entered into a lease agreement, as amended, for its headquarters, pursuant to which the Company leased 22,213 square feet of office and research and development space located at 19 Presidential Way, Woburn, Massachusetts. The lease will terminate on November 30, 2026 and does not include options for an early termination or for an extension of the lease. Pursuant to the lease, the Company is required to pay certain pro rata taxes and operating costs associated with the premises throughout the term of the lease. During the initial buildout of the rented space, the landlord paid for tenant improvements to the facility that result in increased rental payments by the Company. As required by ASC 842, these improvements were recorded as a reduction in the valuation of the associated right-of-use asset. The Company has provided the landlord with a security deposit of $229.

In October 2016, the Company entered into a sublease agreement with a subsidiary of CJ CheilJedang Corporation ("CJ") with respect to CJ's sublease of 9,874 square feet of its leased facility located in Woburn, Massachusetts. The sublease space was determined to be in excess of the Company's needs. The CJ sublease is coterminous with the Company's master lease and CJ will pay pro rata rent and operating expenses proportionate to the amounts payable to the landlord by the Company, as adjusted from time to time in accordance with the terms of the master lease. Future CJ sublease payments have not been presented as an offset to total undiscounted future lease payments of $3,786 shown in the lease maturity analysis table above. CJ provided the Company with a security deposit of $103 in the form of an irrevocable letter of credit.

Through May 2020, the Company leased approximately 13,702 square feet of unused office and laboratory space located in Lowell, Massachusetts. The lease terminated in accordance with the terms of the lease agreement and the facility was returned to the landlord. No further expenses are anticipated under this lease.

The Company's wholly-owned subsidiary, MOI, located in Saskatoon, Saskatchewan, Canada, leases approximately 7,700 square feet of office, laboratory and greenhouse space located within Innovation Place at 410 Downey Road and within the research facility of National Research Council Canada located at 110 Gymnasium Place. None of these leases contain renewal or early termination options. MOI's leases for these facilities expire on various dates through September 2022.

Cares Act Loan	12 Months Ended
Cares Act Loan	Dec. 31, 2021
Debt Disclosure [Abstract]
Cares Act Loan	Cares Act LoanDuring 2020 the Company received $333 in loan proceeds through the Paycheck Protection Program Flexibility Act ("PPP"), established pursuant to the CARES Act. Under the CARES Act and the PPP, a borrower could apply for and be granted forgiveness for all or a part of its PPP loan. The amount of loan proceeds eligible for forgiveness was based on a formula that took into account a number of factors, including the amount of loan proceeds used by the borrower during the twenty-four-week period after the loan origination for certain purposes, including payroll costs, rent payments on certain leases and certain qualified utility payments. During the year ended December 31, 2020, Yield10 utilized the entire PPP Loan amount for qualifying expenses and received a favorable determination to its application for loan forgiveness for the full amount of the loan.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI http://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Income Taxes

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Income Taxes

Income Taxes and Deferred Tax Assets and Liabilities

The components of loss from operations before provision for income taxes consist of the following:


	Year Ended December 31,
	2021		2020
Domestic	$	(11,062)	$	(10,287)
Foreign	67		137
Net loss from operations before income tax provision	$	(10,995)	$	(10,150)

The components of the income tax provision consisted of the following for the years ended December 31, 2021 and 2020:


	Year Ended December 31,
	2021		2020
Current Tax Provision:
Federal	$	—	$	—
State	—		—
Foreign	—		—
Total current	—		—

Deferred Tax Benefit:
Federal	—		—
State	—		—
Foreign	36		56
Total deferred	36		56
Total tax provision	$	36	$	56

Significant components of the Company's deferred tax assets are as follows:


	Year Ended December 31,
	2021		2020
Deferred Tax Assets:
Net operating loss carryforward	$	5,533	$	28,425
Capitalization of research and development expense	—		938
Credit carryforwards	565		2,431
Capital loss carryover	—		646
Stock compensation	886		764
Lease liability	864		993
Other temporary differences	106		338
Total deferred tax assets	7,954		34,535
Valuation allowance	(6,961)		(33,377)
Net deferred tax assets	993		1,158
Deferred Tax Liabilities:
Depreciation	(185)		(216)
Right-of-use asset	(643)		(741)
Net deferred taxes	$	165	$	201

Tax Rate

The items accounting for the difference between the income tax (provision) benefit computed at the federal statutory rate of 21% and the provision for income taxes were as follows:


	Year Ended December 31,
	2021		2020
Federal income tax at statutory federal rate	21.0	%	21.0	%
State taxes	5.9	%	5.1	%
Permanent differences	(0.2)	%	0.2	%
Tax credits	2.0	%	1.7	%
Foreign rate differential	(0.1)	%	(0.1)	%
Impact of ownership change	(267.0)	%	0.0	%
Non-deductible equity transactions	0.0	%	(2.0)	%
Stock compensation	(2.1)	%	(2.6)	%
Other	(0.1)	%	0.0	%
Change in valuation allowance	240.3	%	(23.9)	%
Total	(0.3)	%	(0.6)	%

Tax Attributes

At December 31, 2021, the Company had U.S. net operating loss carryforwards ("NOLs") for federal and state income tax purposes of approximately $20,242 and $20,279, respectively. All of the $20,242 of federal NOLs will carry forward indefinitely. The Company's state NOL carryforwards will begin to expire on various dates through 2041. The Company also had available research and development and investment tax credits for federal and state income tax purposes of approximately $257 and $183, respectively. These federal and state credits will begin to expire on various dates through

2041. In Canada, the Company has cumulative research tax credits totaling $165 that will begin to expire on various dates through 2036.

Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets, which is comprised principally of NOL carryforwards. Under the applicable accounting standards, management has considered the Company's history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of U.S. federal and state deferred tax assets. Accordingly, a full valuation allowance has been established against the U.S. net deferred tax assets. Alternatively, the Company has concluded that it is more likely than not that the net deferred tax assets of its wholly-owned Canadian subsidiary, MOI, totaling $165, will be recognized in the future as a result of annual taxable income generated through MOI's research services and transfer pricing agreements with its U.S. parent.

Utilization of the NOL and research and development credit ("R&D Credit") carryforwards may be subject to a substantial annual limitation under Section 382 of the U.S. Internal Revenue Code of 1986 (the "Code") due to ownership change limitations, as defined by the Code, that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and R&D Credit carryforwards that can be utilized annually to offset future U.S. taxable income and tax, respectively. The Company evaluated its Section 382 ownership changes through May 31, 2021 and has determined that the most recent change that occurred in November 2019 resulted in all NOL and R&D Credit carryforwards outstanding as of that date becoming fully limited. The Company has reduced its associated deferred tax assets accordingly. To the extent an ownership change occurs in the future, the NOL, R&D Credit carryforwards and other deferred tax assets recorded after the November 2019 ownership change may also be subject to limitations.

Other

The tax years 2018 through 2021 remain open to examination by major taxing jurisdictions to which the Company is subject, which are primarily in the U.S. The statute of limitations for NOLs utilized in future years will remain open beginning in the year of utilization.

The Company's policy is to record estimated interest and penalties related to uncertain tax positions as income tax expense. As of December 31, 2021 and 2020, the Company had no accrued interest or penalties recorded related to uncertain tax positions.

No additional provision has been made for U.S. income taxes related to the undistributed earnings of the wholly-owned subsidiaries of Yield10 Bioscience, Inc. or for unrecognized deferred tax liabilities for temporary differences related to investments in subsidiaries as the amounts are not significant. As such, earnings are expected to be permanently reinvested, the investments are essentially permanent in duration, or the Company has concluded that no additional tax liability will arise as a result of the distribution of such earnings. A liability could arise if amounts are distributed by such subsidiaries or if such subsidiaries are ultimately disposed. It is not practical to estimate the additional income taxes related to permanently reinvested earnings or the basis differences related to investment in subsidiaries. Unremitted earnings at December 31, 2021 and December 31, 2020 approximated $1,032 and $999, respectively.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 17
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-URI http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 270
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-URI http://asc.fasb.org/topic&trid=2144680

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

+ Details

Employee Benefits	12 Months Ended
Employee Benefits	Dec. 31, 2021
Retirement Benefits [Abstract]
Employee Benefits	Employee BenefitsThe Company maintains a 401(k) savings plan in which substantially all of its regular U.S. employees are eligible to participate. Participants may contribute up to 60% of their annual compensation to the plan, subject to eligibility requirements and annual IRS limitations. The Company's plan provides for a matching contribution in common stock of up to 4.5% of a participant's total compensation dependent upon the level of participant contributions made during the plan year. Pursuant to this plan, the Company issued 13,611, and 20,788 shares of common stock during the years ended December 31, 2021, and December 31, 2020, respectively, and recorded $112, and $108, respectively, of related expense. Company contributions are fully vested upon issuance.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 55
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section S99
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (o)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (p)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 70
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 60
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (q)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (l)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-URI http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920

+ Details

Government Research Grants	12 Months Ended
Government Research Grants	Dec. 31, 2021
Research and Development Arrangement with Federal Government [Abstract]
Government Research Grants	Government Research GrantsCanadian Research Grants On February 26, 2021, MOI received a research grant through the Industrial Research Assistance Program ("IRAP") administered by National Research Council Canada ("NRC"). The objective of the grant was to provide financial research assistance to innovative, early-stage small and medium-sized enterprises. Under the terms of the agreement, NRC agreed to contribute up to a maximum of $39 for payroll costs incurred by MOI during the period December 20, 2020 - March 13, 2021. During the first quarter of 2021, MOI submitted claims for eligible payroll costs and recognized grant revenue for the full amount of the award. During 2020, MOI received two short-term grants, similar to the 2021 IRAP grant, both of which provided financial research assistance, in the amounts of $67 and $86, respectively, for eligible payroll costs. MOI submitted claims for the eligible costs during 2020 and the full amount of these grants was received and recognized as grant revenue during the year ended December 31, 2020. U.S. Research Grants During 2018 the Company entered into a sub-award with Michigan State University ("MSU") to support a Department of Energy ("DOE") funded grant entitled "A Systems Approach to Increasing Carbon Flux to Seed Oil." The Company's participation under this five-year grant has been awarded incrementally on an annual basis with the first year commencing September 15, 2017. Cumulative funding for this sub-award in the amount of $2,957 has been appropriated by the U.S. Congress through the final contractual year ending in September 2022. During the years ended December 31, 2021 and December 31, 2020, Yield10 recognized grant revenue of $575 and $646, respectively, from this sub-award. As of December 31, 2021, proceeds of $510 remain to be earned from the MSU sub-award amounts awarded to date. This includes amounts for reimbursement to our subcontractors, as well as reimbursement for employees’ time, benefits and other expenses related to future performance.

Geographic Information

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Geographic Information

The geographic distribution of the Company's revenues and long-lived assets are summarized in the table below. Foreign revenue is based on the country in which the Company's subsidiary that earned the revenue is domiciled.


	U.S.		Canada		Total
Year Ended December 31, 2021
Revenue	$	575	$	39	$	614
Identifiable long-lived assets	$	821	$	69	$	890
Year Ended December 31, 2020
Revenue	$	646	$	153	$	799
Identifiable long-lived assets	$	866	$	55	$	921

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

Related Party Transaction	12 Months Ended
Related Party Transaction	Dec. 31, 2021
Related Party Transactions [Abstract]
Related Party Transaction	Related Party Transaction During 1999, the Company entered into a technology sublicense agreement with Tepha, Inc. ("Tepha"), a privately held company engaged in the development of medical products. At the time the sublicense was executed, a director of Yield10 was also the president, chief executive officer and a director of Tepha. Three other members of Yield10's board of directors also served on the board of directors of Tepha, of which one continued to serve until completion of the merger of Tepha discussed below. Yield10 received 648,149 shares of Series A Convertible Preferred Stock of Tepha ("Tepha Shares") during 2002 as consideration for outstanding license payments due to Yield10 totaling $700. During 2005, the Company determined the value of the Tepha Shares was impaired resulting in their write off through a charge to other income (expense). The sublicense agreement with Tepha ended in 2016. In May 2021, the board of directors of Tepha approved and authorized the merger of Tepha with Becton Dickinson Global Holdings, Inc. On July 26, 2021, Yield10 received cash consideration of $700 in exchange for the surrender of its Tepha Shares upon the closing of the merger. The Company recorded the $700 as a gain on investment in related party within other income (expense) for the year ended December 31, 2021.

Summary of Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Basis of Presentation

Principles of Consolidation

Use of Estimates

Cash and Cash Equivalents

Cash, Cash Equivalents and Restricted Cash

The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.

Restricted Cash

Investments

Foreign Currency Translation

Comprehensive Loss

Concentration of Credit Risk

Fair Value Measurements

Segment Information

Property and Equipment


Asset Description						Estimated Useful Life (years)
Equipment						3
Furniture and fixtures						5
Software						3
Leasehold improvements						Shorter of useful life or term of lease

Lease Accounting

Lease AccountingAs a lessee, the Company follows the lease accounting guidance codified in ASC 842. A lease is classified as a finance lease if any of five criteria described in the guidance apply to the lease and any lease not classified as a finance lease is classified as an operating lease with expense recognition occurring on a straight-line basis over the term of the lease. Under ASC 842, the Company records a lease liability on the commencement date of a lease calculated as the present value of the lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the Company's incremental borrowing rate. A right-of-use asset equal to the lease liability is also recorded with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs and lessor lease incentives that may be present within the terms of the lease. The Company adopted the short-term lease exception that permits lessees to omit leases with terms of twelve months or less from the accounting requirements of ASC 842.

Impairment of Long-Lived Assets

Grant Revenue

Research and Development

General, and Administrative Expenses

General and Administrative Expenses

Intellectual Property Costs

The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the consolidated statement of operations.

Stock-Based Compensation

Basic and Diluted Net Loss per Share

Income Taxes

See Note 13 for further discussion of income taxes. The Company had no amounts recorded for unrecognized tax benefits as of December 31, 2021 and 2020.

Recent Accounting Standards Changes

The following new pronouncement is not yet effective but may impact the Company's consolidated financial statements in the future.

Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2021

Accounting Policies [Abstract]

Reconciliation of cash, cash equivalents and restricted cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's consolidated balance sheets included herein:


	December 31, 2021		December 31, 2020
Cash and cash equivalents	$	5,329	$	3,423
Restricted cash	264		264
Total cash, cash equivalents and restricted cash	$	5,593	$	3,687

Schedule of estimated useful life of assets used to compute depreciation using the straight-line method

Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:


Asset Description						Estimated Useful Life (years)
Equipment						3
Furniture and fixtures						5
Software						3
Leasehold improvements						Shorter of useful life or term of lease

Property and equipment consist of the following:


	Year ended December 31,
	2021		2020
Equipment	$	581	$	766
Furniture and fixtures	43		43
Leasehold improvements	1,420		1,414
Software	14		22
Total property and equipment, at cost	2,058		2,245
Less: accumulated depreciation and amortization	(1,168)		(1,324)
Property and equipment, net	$	890	$	921

Schedule of shares used to calculate diluted earnings per share

The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their antidilutive effect:


	Year Ended December 31,
	2021	2020
Options	722,765	339,108
Restricted stock awards	9,430	8,500


Warrants	2,361,726	2,843,699
Total	3,093,921	3,191,307

Investments (Tables)

12 Months Ended

Dec. 31, 2021

Investments, Debt and Equity Securities [Abstract]

Schedule of investment holdings

The Company's investments consist of the following:


	Accumulated Cost at December 31, 2021		Unrealized				Market Value at December 31, 2021
			Gain		(Loss)
Short-term investments
U.S. government and agency securities	$	10,669	$	—	$	(8)	$	10,661
Total	$	10,669	$	—	$	(8)	$	10,661


	Accumulated Cost at December 31, 2020		Unrealized				Market Value at December 31, 2020
			Gain		(Loss)
Short-term investments
U.S. government and agency securities	$	6,279	$	—	$	—	$	6,279
Total	$	6,279	$	—	$	—	$	6,279

Fair Value Measurements (Tables)

12 Months Ended

Dec. 31, 2021

Fair Value Disclosures [Abstract]

Assets and liabilities measured at fair value on a recurring basis


	Fair value measurements at December 31, 2021
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		December 31, 2021
Assets
Cash equivalents:
Money market funds	$	4,878	$	—	$	—	$	4,878

Short-term investments:
U.S. government and agency securities	—		10,661		—		10,661
Total assets	$	4,878	$	10,661	$	—	$	15,539


	Fair value measurements at December 31, 2020
	Quoted prices in active markets for identical assets		Significant other observable inputs		Significant unobservable inputs		Balance as of
Description	(Level 1)		(Level 2)		(Level 3)		December 31, 2020
Assets
Cash equivalents:
Money market funds	$	2,873	$	—	$	—	$	2,873
Short-term investments:
U.S. government and agency securities	—		6,279		—		6,279
Total assets	$	2,873	$	6,279	$	—	$	9,152

Reconciliation of beginning and ending balances for the Level 3 warrant liability

The following tables show a reconciliation of the beginning and ending balances for the Level 3 warrant liability for the year ending December 31, 2020.


	Year ended December 31, 2020
Warrant liability, December 31, 2019	$	14,977
Recognized loss from mark-to-market adjustment prior to reclassification of warrant liability to equity	957
Reclassification from warrant liability to equity	(15,934)
Warrant liability, December 31, 2020	$	—

Property and Equipment, Net (Tables)

12 Months Ended

Dec. 31, 2021

Property, Plant and Equipment [Abstract]

Schedule of components of property and equipment

Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:


Asset Description						Estimated Useful Life (years)
Equipment						3
Furniture and fixtures						5
Software						3
Leasehold improvements						Shorter of useful life or term of lease

Property and equipment consist of the following:


	Year ended December 31,
	2021		2020
Equipment	$	581	$	766
Furniture and fixtures	43		43
Leasehold improvements	1,420		1,414
Software	14		22
Total property and equipment, at cost	2,058		2,245
Less: accumulated depreciation and amortization	(1,168)		(1,324)
Property and equipment, net	$	890	$	921

Accrued Expenses (Tables)

12 Months Ended

Dec. 31, 2021

Payables and Accruals [Abstract]

Schedule of accrued expenses

Accrued expenses consist of the following:


	Year ended December 31,
	2021		2020
Employee compensation and benefits	$	452	$	620
Leased facilities	71		188
Professional services	264		235
Field trials and related expenses	97		52
Other	252		202
Total accrued expenses	$	1,136	$	1,297

Capital Stock and Warrants (Tables)

12 Months Ended

Dec. 31, 2021

Equity [Abstract]

Information with regard to outstanding warrants to purchase common stock

The following table summarizes information with regard to outstanding warrants to purchase common stock as of December 31, 2021:


Issuance	Number of Common Shares Issuable Upon Exercise of Outstanding Warrants	Exercise Price		Expiration Date
November 2019 Public Offering - Series A	352,703	$	8.00	May 19, 2022
November 2019 Public Offering - Series B	395,528	$	8.00	May 19, 2027
November 2019 Private Placement - Series A	718,750	$	8.00	May 19, 2022
November 2019 Private Placement - Series B	718,750	$	8.00	May 19, 2027
December 2017 Public Offering - Series A	160,975	$	90.00	December 21, 2022
July 2017 Registered Direct Offering	14,270	$	201.60	January 7, 2024
Consultant	750	$	116.00	September 11, 2024
Total	2,361,726

Schedule of primary rights of convertible preferred stockholders, and common stock shares reserved for future issuance

The following shares of common stock were reserved for future issuance upon exercise of stock options, vesting of Restricted Stock Units ("RSUs") and conversion of outstanding warrants:


	December 31, 2021	December 31, 2020
Stock Options	722,765	339,108
RSUs	9,430	8,500
Warrants	2,361,726	2,843,699
Total number of common shares reserved for future issuance	3,093,921	3,191,307

- Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644

+ Details

Stock-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2021

Share-based Payment Arrangement [Abstract]

Summary of the activity related to the shares of common stock covered by outstanding options under the plans

A summary of the activity related to the shares of common stock covered by outstanding options is as follows:


	Number of Shares	Weighted Average Exercise Price		Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Balance at December 31, 2020	339,108	$	32.39
Granted	386,017	10.08
Exercised	—	—
Forfeited	(1,509)	12.92
Expired	(851)	1,131.62
Balance at December 31, 2021	722,765	19.22		8.79	$	—
Vested and expected to vest at December 31, 2021	722,765	19.22		8.79	$	—
Exercisable at December 31, 2021	213,156	43.15		8.07	$	—

Schedule of assumptions used in determining fair value of stock options granted using the Black-Scholes option pricing model


	Year Ended December 31,
	2021	2020
Expected dividend yield	—	—
Risk-free rate	0.7% - 1.7%	0.5% - 1.9%
Expected option term (in years)	6.1 - 10.0	6.1 - 10.0
Volatility	118% - 128%	111% - 129%

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity

A summary of RSU activity for the year ended December 31, 2021 is as follows:


	Number of RSUs	Weighted Average Remaining Contractual Life (years)
Outstanding at December 31, 2020	8,500
Awarded	18,862
Released	(17,932)
Forfeited	—
Outstanding at December 31, 2021	9,430	0.16

Weighted average remaining recognition period (years)	0.16

Leases (Tables)

12 Months Ended

Dec. 31, 2021

Leases [Abstract]

Maturity analysis of lease liabilities


Year ended December 31,	Undiscounted Cash Flows
2022	$	726
2023	749
2024	771
2025	793
2026	747
Total undiscounted future lease payments	3,786
Amount of lease payments representing interest	(623)
Total lease liabilities	$	3,163
Short-term lease liabilities	$	514
Long-term lease liabilities	$	2,649

Quantitative disclosure of lease costs

Quantitative Disclosure of Lease Costs


	Year Ended December 31,
	2021		2020
Lease cost:
Operating lease cost	$	605	$	688
Short-term lease cost	655		676
Sublease income	(616)		(560)
Total lease cost, net	$	644	$	804


Other information as of:	December 31, 2021	December 31, 2020
Weighted-average remaining lease term (years)	4.9	5.9
Weighted-average discount rate	7.25%	7.25%

Income Taxes (Tables)

12 Months Ended

Dec. 31, 2021

Income Tax Disclosure [Abstract]

Schedule of components of profit (loss) before provision for income taxes

The components of loss from operations before provision for income taxes consist of the following:


	Year Ended December 31,
	2021		2020
Domestic	$	(11,062)	$	(10,287)
Foreign	67		137
Net loss from operations before income tax provision	$	(10,995)	$	(10,150)

Components of income tax benefit

The components of the income tax provision consisted of the following for the years ended December 31, 2021 and 2020:


	Year Ended December 31,
	2021		2020
Current Tax Provision:
Federal	$	—	$	—
State	—		—
Foreign	—		—
Total current	—		—

Deferred Tax Benefit:
Federal	—		—
State	—		—
Foreign	36		56
Total deferred	36		56
Total tax provision	$	36	$	56

Schedule of significant components of the Company's net deferred tax asset

Significant components of the Company's deferred tax assets are as follows:


	Year Ended December 31,
	2021		2020
Deferred Tax Assets:
Net operating loss carryforward	$	5,533	$	28,425
Capitalization of research and development expense	—		938
Credit carryforwards	565		2,431
Capital loss carryover	—		646
Stock compensation	886		764
Lease liability	864		993
Other temporary differences	106		338
Total deferred tax assets	7,954		34,535
Valuation allowance	(6,961)		(33,377)
Net deferred tax assets	993		1,158
Deferred Tax Liabilities:
Depreciation	(185)		(216)
Right-of-use asset	(643)		(741)
Net deferred taxes	$	165	$	201

Schedule of items accounting for the difference between the income tax benefit computed at the federal statutory rate and the provision for income taxes

The items accounting for the difference between the income tax (provision) benefit computed at the federal statutory rate of 21% and the provision for income taxes were as follows:


	Year Ended December 31,
	2021		2020
Federal income tax at statutory federal rate	21.0	%	21.0	%
State taxes	5.9	%	5.1	%
Permanent differences	(0.2)	%	0.2	%
Tax credits	2.0	%	1.7	%
Foreign rate differential	(0.1)	%	(0.1)	%
Impact of ownership change	(267.0)	%	0.0	%
Non-deductible equity transactions	0.0	%	(2.0)	%
Stock compensation	(2.1)	%	(2.6)	%
Other	(0.1)	%	0.0	%
Change in valuation allowance	240.3	%	(23.9)	%
Total	(0.3)	%	(0.6)	%

Geographic Information (Tables)

12 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Schedule of the geographic distribution of revenues and long-lived assets from continuing operations


	U.S.		Canada		Total
Year Ended December 31, 2021
Revenue	$	575	$	39	$	614
Identifiable long-lived assets	$	821	$	69	$	890
Year Ended December 31, 2020
Revenue	$	646	$	153	$	799
Identifiable long-lived assets	$	866	$	55	$	921

Nature of Business and Basis of Presentation (Details) $ in Thousands	Dec. 31, 2021 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Unrestricted cash, cash equivalents and short-term investments	$ 15,990

Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Cash and cash equivalents	$ 5,329	$ 3,423
Restricted cash	264	264
Total cash, cash equivalents and restricted cash	$ 5,593	$ 3,687	$ 5,749

Summary of Significant Accounting Policies - Estimated Useful Lives (Details)	12 Months Ended
	Dec. 31, 2021
Equipment
Property and Equipment
Estimated Useful Life	3 years
Furniture and fixtures
Property and Equipment
Estimated Useful Life	5 years
Software
Property and Equipment
Estimated Useful Life	3 years

Summary of Significant Accounting Policies - Antidilutive Common Stock Excluded From Calculation of Dilutive Shares (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	3,093,921	3,191,307
Options
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	722,765	339,108
Restricted stock awards
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	9,430	8,500
Warrants
Antidilutive securities
Antidilutive common stock excluded from the calculation of dilutive shares	2,361,726	2,843,699

Summary of Significant Accounting Policies - Narrative (Details)		12 Months Ended
	Jan. 15, 2020	Dec. 31, 2021 USD ($) segment	Dec. 31, 2020 USD ($)
Concentration of credit risk
Reverse stock split, conversion ratio	0.025
Restricted cash		$ 264,000	$ 264,000
Long-term investments		0	0
Accounts and unbilled receivables		198,000	113,000
Unbilled receivables, current		$ 27,000
Number of operating segments \| segment		1
Unrecognized tax benefits		$ 0	0
Revenues \| Customer Concentration Risk \| Michigan State University
Concentration of credit risk
Percentage of total revenue		94.00%
U.S Government Grants
Concentration of credit risk
Accounts and unbilled receivables			$ 86,000

Investments (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Short-term Investments [Abstract]
Accumulated Cost	$ 10,669,000	$ 6,279,000
Unrealized Gain	0	0
Unrealized (Loss)	(8,000)	0
Market Value	10,661,000	6,279,000
Long-term investments	0	0
Government securities
Short-term Investments [Abstract]
Accumulated Cost	10,669,000	6,279,000
Unrealized Gain	0	0
Unrealized (Loss)	(8,000)	0
Market Value	$ 10,661,000	$ 6,279,000

Fair Value Measurements - Narrative (Details) $ in Thousands		3 Months Ended	12 Months Ended
	Jan. 15, 2020 USD ($)	Mar. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Nov. 19, 2019 USD ($)
Fair Value Disclosures [Abstract]
Reverse stock split, conversion ratio	0.025
Warrant liability	$ 15,934				$ 24,518
Gain (loss) from change in fair value or warrants	$ 957	$ (9,541)	$ 0	$ 957

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	$ 10,661	$ 6,279
U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	10,661	6,279
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	15,539	9,152
Fair Value, Measurements, Recurring \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	10,661	6,279
Fair Value, Measurements, Recurring \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	4,878	2,873
Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	4,878	2,873
Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (Level 1) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Fair Value, Measurements, Recurring \| Quoted prices in active markets for identical assets (Level 1) \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	4,878	2,873
Fair Value, Measurements, Recurring \| Significant other observable inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	10,661	6,279
Fair Value, Measurements, Recurring \| Significant other observable inputs (Level 2) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	10,661	6,279
Fair Value, Measurements, Recurring \| Significant other observable inputs (Level 2) \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	0	0
Fair Value, Measurements, Recurring \| Significant unobservable inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	0	0
Fair Value, Measurements, Recurring \| Significant unobservable inputs (Level 3) \| U.S. government and agency securities
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Short-term investments	0	0
Fair Value, Measurements, Recurring \| Significant unobservable inputs (Level 3) \| Money market funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash equivalents	$ 0	$ 0

Fair Value Measurements - Level 3 Rollforward of Warrant Liability (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020 USD ($)
Fair Value Disclosures [Abstract]
Warrant liability, December 31, 2019	$ 14,977
Recognized gain (loss) from mark-to-market adjustments	957
Reclassification from warrant liability to equity	(15,934)
Warrant liability, December 31, 2020	$ 0

Property and Equipment, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property and equipment, net
Total property and equipment, at cost	$ 2,058	$ 2,245
Less: accumulated depreciation and amortization	(1,168)	(1,324)
Property and equipment, net	890	921
Depreciation and amortization	220	182
Equipment
Property and equipment, net
Total property and equipment, at cost	581	766
Furniture and fixtures
Property and equipment, net
Total property and equipment, at cost	43	43
Leasehold improvements
Property and equipment, net
Total property and equipment, at cost	1,420	1,414
Software
Property and equipment, net
Total property and equipment, at cost	$ 14	$ 22

Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Employee compensation and benefits	$ 452	$ 620
Leased facilities	71	188
Professional services	264	235
Field trials and related expenses	97	52
Other	252	202
Total accrued expenses	$ 1,136	$ 1,297

Commitments and Contingencies (Details) - Collaborative Arrangement - USD ($) $ in Thousands	Nov. 12, 2020	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Quarterly research funding and option fees	$ 31
Total research funding and option fees	$ 250	$ 125
Term of agreement	2 years
Term of option for license agreement	2 years

License Agreements (Details)	1 Months Ended
License Agreements (Details)	Sep. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License agreement term	3 years

Capital Stock and Warrants - Narrative (Details) $ / shares in Units, $ in Thousands					1 Months Ended	3 Months Ended	12 Months Ended
	Feb. 03, 2021 USD ($) $ / shares shares	Aug. 26, 2020 USD ($) $ / shares shares	Jan. 15, 2020 USD ($) shares	Nov. 19, 2019 USD ($) $ / shares shares	Dec. 31, 2017 shares	Mar. 31, 2021 USD ($)	Dec. 31, 2021 USD ($) $ / shares shares	Dec. 31, 2020 USD ($) $ / shares shares	Apr. 30, 2020 shares
Class of Stock [Line Items]
Reverse stock split, conversion ratio			0.025
Common stock, shares authorized (in shares)			60,000,000				60,000,000	60,000,000
Gross proceeds from transaction \| $				$ 11,500
Number of securities called by warrants (in shares)				2,875,000			2,361,726
Warrant liability \| $			$ 15,934	$ 24,518
Gain (loss) from change in fair value or warrants \| $			$ 957			$ (9,541)	$ 0	$ 957
Preferred stock, shares authorized							5,000,000	5,000,000
Preferred stock, par value per share (in dollars per share) \| $ / shares							$ 0.01	$ 0.01
Issuance of preferred stock in connection with private offering (in shares)				5,750				0
Proceeds from warrants exercised \| $							$ 3,856	$ 1,658
Common Stock
Class of Stock [Line Items]
Shares issued (in shares)			718,750
Issuance of stock (in shares)							1,040,000	1,348,285
Shares issued cumulative (in shares)									313,000
Warrants exercised (in shares)							481,973
Series B Warrants
Class of Stock [Line Items]
Exercise price of warrants (in USD per share) \| $ / shares				$ 8.00
Series A Convertible Preferred Stock
Class of Stock [Line Items]
Issuance of stock (in shares)					2,504
Series A Convertible Preferred Stock \| Common Stock
Class of Stock [Line Items]
Issuance of stock (in shares)								99,500
Class B Units \| Series A Warrants
Class of Stock [Line Items]
Number of securities called by each warrant or right (in shares)				125
Public offering
Class of Stock [Line Items]
Common stock issued in offering (in shares)	1,040,000	951,835
Common stock price (in dollars per share) \| $ / shares	$ 12.25	$ 4.25
Gross proceeds \| $	$ 12,740	$ 4,045
Issuance costs \| $	$ 747	$ 425
Registered direct offering
Class of Stock [Line Items]
Common stock issued in offering (in shares)		396,450
Common stock price (in dollars per share) \| $ / shares		$ 4.25
Gross proceeds \| $		$ 1,685
Public and private offerings
Class of Stock [Line Items]
Issuance costs \| $				$ 1,254

Capital Stock and Warrants - Schedule Of Warrants Issuance (Details) - $ / shares	Dec. 31, 2021	Nov. 19, 2019
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	2,361,726	2,875,000
Warrants - expiration January 2024
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	14,270
Exercise Price (in USD per share)	$ 201.60
Warrants - expiration September 2024
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	750
Exercise Price (in USD per share)	$ 116.00
Public offering \| Series A Warrants - expiration May 2022
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	352,703
Exercise Price (in USD per share)	$ 8.00
Public offering \| Series B Warrants - expiration May 2027
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	395,528
Exercise Price (in USD per share)	$ 8.00
Public offering \| Series A Warrants - expiration December 2022
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	160,975
Exercise Price (in USD per share)	$ 90.00
Registered direct offering \| Series A Warrants - expiration May 2022
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	718,750
Exercise Price (in USD per share)	$ 8.00
Registered direct offering \| Series B Warrants - expiration May 2027
Class of Stock [Line Items]
Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)	718,750
Exercise Price (in USD per share)	$ 8.00

Capital Stock and Warrants - Schedule of Common Stock Reserved For Future Issuance (Details) - shares	Dec. 31, 2021	Dec. 31, 2020
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	3,093,921	3,191,307
Options
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	722,765	339,108
Restricted Stock Units (RSUs)
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	9,430	8,500
Warrants
Class of Stock [Line Items]
Total number of common shares reserved for future issuance	2,361,726	2,843,699

Stock-Based Compensation - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands							12 Months Ended		37 Months Ended
	Jan. 01, 2022	May 24, 2021	Jan. 01, 2021	May 19, 2020	Jan. 01, 2020	Jan. 01, 2019	Dec. 31, 2021	Dec. 31, 2020	Jan. 31, 2022	Dec. 31, 2019
Stock-based compensation
Unvested and outstanding restricted stock (in shares)							9,430	8,500
Increase in shares available for issuance, percent			5.00%		5.00%	5.00%
Stock-based compensation							$ 1,675	$ 739
RSUs awarded (in shares)							18,862
Fair value of vested shares withheld for minimum tax withholding							$ 103	$ 17
2018 Stock Plan
Stock-based compensation
Shares reserved for issuance										32,500
Additional shares authorized		300,000		250,000
Options and restricted stock awards issued (in shares)							745,184
Options and restricted stock awards outstanding (in shares)							715,244
Stock options
Stock-based compensation
Unvested and outstanding options (in shares)							722,765	339,108
Expiration period							10 years
Weighted average grant date fair value of options granted (in dollars per share)							$ 8.99	$ 5.31
Weighted average remaining contractual term for options outstanding							8 years 9 months 14 days
Exercise of common stock options (in shares)							0	0
Stock options \| Employee and Director
Stock-based compensation
Stock-based compensation expense, net of estimated forfeitures, related to unvested awards not yet recognized							$ 4,036
Weighted average period over which unrecognized compensation expense is expected to be recognized							2 years 11 months 15 days
Stock options \| Minimum
Stock-based compensation
Vesting period for options granted							1 year
Stock options \| Maximum
Stock-based compensation
Vesting period for options granted							4 years
Stock options \| 2006 Plan
Stock-based compensation
Options awarded to date (in shares)							3,662
Unvested and outstanding options (in shares)							364
Stock options \| 2014 Plan
Stock-based compensation
Options awarded to date (in shares)							16,896
Unvested and outstanding options (in shares)							16,108
Restricted stock awards \| 2014 Plan
Stock-based compensation
Options awarded to date (in shares)							3,619
Restricted Stock Units (RSUs)
Stock-based compensation
Fair value of vested shares withheld for minimum tax withholding							$ 102	$ 17
Subsequent Event
Stock-based compensation
Increase in shares available for issuance, percent	5.00%
Subsequent Event \| 2018 Stock Plan
Stock-based compensation
Additional shares authorized									469,998

Stock-Based Compensation - Stock Option Activity (Details) - Stock options - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Number of Shares
Balance at the beginning of the period (in shares)	339,108
Granted (in shares)	386,017
Exercised (in shares)	0	0
Forfeited (in shares)	(1,509)
Expired (in shares)	(851)
Balance at the end of the period (in shares)	722,765	339,108
Vested and expected to vest at the end of the period (in shares)	722,765
Options exercisable at the end of the period (in shares)	213,156
Weighted Average Exercise Price
Balance at the beginning of the period (in dollars per share)	$ 32.39
Granted (in dollars per share)	10.08
Exercised (in dollars per share)	0
Forfeited (in dollars per share)	12.92
Expired (in dollars per share)	1,131.62
Balance at the end of the period (in dollars per share)	19.22	$ 32.39
Vested and expected to vest at the end of the period (in dollars per share)	19.22
Exercisable at the end of the period (in dollars per share)	$ 43.15
Remaining Contractual Term
Balance	8 years 9 months 14 days
Vested and expected to vest	8 years 9 months 14 days
Exercisable	8 years 25 days
Aggregate Intrinsic Value
Balance	$ 0
Vested and expected to vest	0
Exercisable	$ 0

Stock-Based Compensation - Assumptions Used for Fair Value of Stock Options (Details) - Stock options	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Assumptions used to determine fair value of stock options
Expected dividend yield	0.00%	0.00%
Risk-free rate, minimum	0.70%	0.50%
Risk-free rate, maximum	1.70%	1.90%
Volatility, minimum	118.00%	111.00%
Volatility, maximum	128.00%	129.00%
Minimum
Assumptions used to determine fair value of stock options
Expected option term	6 years 1 month 6 days	6 years 1 month 6 days
Maximum
Assumptions used to determine fair value of stock options
Expected option term	10 years	10 years

Stock-Based Compensation - Restricted Stock Units (RSUs) (Details)	12 Months Ended
	Dec. 31, 2021 shares
Number of RSUs
Outstanding (in shares)	8,500
Awarded (in shares)	18,862
Released (in shares)	(17,932)
Forfeited (in shares)	0
Outstanding (in shares)	9,430
Weighted average remaining contractual life	1 month 28 days

Leases - Maturity Analysis of Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
2022	$ 726
2023	749
2024	771
2025	793
2026	747
Total undiscounted future lease payments	3,786
Amount of lease payments representing interest	(623)
Total lease liabilities	3,163
Short-term lease liabilities	514	$ 457
Long-term lease liabilities	$ 2,649	$ 3,163

Leases - Quantitative Disclosure of Lease Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Lease cost:
Operating lease cost	$ 605	$ 688
Short-term lease cost	655	676
Sublease income	(616)	(560)
Total lease cost, net	$ 644	$ 804
Other information as of:
Weighted-average remaining lease term	4 years 10 months 24 days	5 years 10 months 24 days
Weighted-average discount rate	7.25%	7.25%

Leases - Narrative (Details) $ in Thousands	1 Months Ended	12 Months Ended
Leases - Narrative (Details) $ in Thousands	Oct. 31, 2016 USD ($) ft²	Dec. 31, 2021 USD ($) ft²	Dec. 31, 2016 ft²	Nov. 30, 2019 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Undiscounted future lease payments \| $		$ 3,786
19 Presidential Way, Woburn, Massachusetts
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Leased area (in sqft)			22,213
Security deposit - letter of credit \| $	$ 103			$ 229
Subleased area (in sqft)	9,874
Undiscounted future lease payments \| $		$ 3,786
650 Suffolk Street, Lowell, Massachusetts
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Leased area (in sqft)		13,702
410 Downey Road and 110 Gymnasium Place
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Leased area (in sqft)		7,700

Cares Act Loan (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
Cares Act Loan (Details) - USD ($) $ in Thousands	Apr. 30, 2020	Dec. 31, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Proceeds from PPP loan	$ 333	$ 0	$ 333

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Components of profit (loss) before provision for income taxes
Domestic	$ (11,062)	$ (10,287)
Foreign	67	137
Loss from operations before income taxes	(10,995)	(10,150)
Current Tax Provision:
Federal	0	0
State	0	0
Foreign	0	0
Total current	0	0
Deferred Tax Benefit:
Federal	0	0
State	0	0
Foreign	36	56
Total deferred	36	56
Total tax provision	36	56
Deferred Tax Assets:
Net operating loss carryforward	5,533	28,425
Capitalization of research and development expense	0	938
Credit carryforwards	565	2,431
Capital loss carryover	0	646
Stock compensation	886	764
Lease liability	864	993
Other temporary differences	106	338
Total deferred tax assets	7,954	34,535
Valuation allowance	(6,961)	(33,377)
Net deferred tax assets	993	1,158
Deferred Tax Liabilities:
Depreciation	(185)	(216)
Right-of-use asset	(643)	(741)
Net deferred taxes	$ 165	$ 201
Difference between income tax benefit computed at the federal statutory rate and the provision for income taxes
Federal income tax at statutory federal rate	21.00%	21.00%
State taxes	5.90%	5.10%
Permanent differences	(0.20%)	0.20%
Tax credits	2.00%	1.70%
Foreign rate differential	(0.001)	(0.001)
Impact of ownership change	(267.00%)	0.00%
Non-deductible equity transactions	0.00%	(2.00%)
Stock compensation	(2.10%)	(2.60%)
Other	(0.10%)	0.00%
Change in valuation allowance	240.30%	(23.90%)
Total	(0.30%)	(0.60%)

Income Taxes - Details Textual (Details) - USD ($)	12 Months Ended
Income Taxes - Details Textual (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Income Tax Contingency [Line Items]
Interest and penalties accrued	$ 0	$ 0
Provision for income taxes for undistributed earnings of foreign subsidiaries	0
Undistributed earnings of foreign subsidiaries	1,032,000	$ 999,000
Internal Revenue Service (IRS)
Income Tax Contingency [Line Items]
Net operating loss carryforwards	20,242,000
State and Local Jurisdiction
Income Tax Contingency [Line Items]
Net operating loss carryforwards	20,279,000
Research Tax Credit Carryforward \| Internal Revenue Service (IRS)
Income Tax Contingency [Line Items]
Tax credit carryforward, amount	257,000
Research Tax Credit Carryforward \| State and Local Jurisdiction
Income Tax Contingency [Line Items]
Tax credit carryforward, amount	183,000
Research Tax Credit Carryforward \| Foreign Tax Authority
Income Tax Contingency [Line Items]
Tax credit carryforward, amount	$ 165,000

Employee Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
Employee Benefits (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Retirement Benefits [Abstract]
Maximum contribution by participants under the 401(k) savings plan (as a percent)	60.00%
Employer's matching contribution in common stock as a percentage of a participant's total compensation, percent	4.50%
Common stock issued under the 401(k) savings plan (in shares)	13,611	20,788
Related expense for common stock issued under the 401(k) savings plan	$ 112	$ 108

Government Research Grants (Details) - USD ($) $ in Thousands		12 Months Ended
	Sep. 15, 2017	Dec. 31, 2021	Dec. 31, 2020	Feb. 26, 2021
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum payroll cost reimbursement				$ 39
Government grant term	5 years
Revenues		$ 614	$ 799
Grant 1
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum payroll cost reimbursement			67
Grant 2
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Maximum payroll cost reimbursement			86
Systems Approach to Increasing Carbon Flux to Seed Oil
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Cumulative amount awarded		2,957
Grant revenue
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues		614	799
Grant revenue \| Systems Approach to Increasing Carbon Flux to Seed Oil
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Revenues		575	$ 646
Amount remaining to be earned		$ 510

Geographic Information (Details) - USD ($) $ in Thousands	12 Months Ended
Geographic Information (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Geographic Information
Revenue	$ 614	$ 799
Identifiable long-lived assets	890	921
U.S.
Geographic Information
Identifiable long-lived assets	821	866
Canada
Geographic Information
Identifiable long-lived assets	69	55
Reportable Geographical Components
Geographic Information
Revenue	614	799
Reportable Geographical Components \| U.S.
Geographic Information
Revenue	575	646
Reportable Geographical Components \| Canada
Geographic Information
Revenue	$ 39	$ 153

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Geographic Information - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue earned
Revenues	$ 614	$ 799
Customer Concentration Risk \| Revenues \| Michigan State University
Revenue earned
Percentage of total revenue	94.00%
Grant revenue
Revenue earned
Revenues	$ 614	799
Grant revenue \| Systems Approach to Increasing Carbon Flux to Seed Oil
Revenue earned
Revenues	$ 575	$ 646

- Definition

+ References

+ Details

Related Party Transaction (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2002
Related Party Transaction [Line Items]
Gain on investment in related party	$ 700	$ 0
Affiliated Entity
Related Party Transaction [Line Items]
Investment (in shares)			648,149
Outstanding license payments			$ 700
Gain on investment in related party	$ 700